Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

453 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.
O'Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, André F, Loibl S, Loi S, Garcia-Murillas I, Cristofanilli M, Huang Bartlett C, Turner NC. O'Leary B, et al. Among authors: cristofanilli m. Cancer Discov. 2018 Nov;8(11):1390-1403. doi: 10.1158/2159-8290.CD-18-0264. Epub 2018 Sep 11. Cancer Discov. 2018. PMID: 30206110 Free PMC article. Clinical Trial.
Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors.
Hanrahan EO, Broglio KR, Buzdar AU, Theriault RL, Valero V, Cristofanilli M, Yin G, Kau SW, Hortobagyi GN, Rivera E. Hanrahan EO, et al. Among authors: cristofanilli m. Cancer. 2005 Sep 15;104(6):1158-71. doi: 10.1002/cncr.21305. Cancer. 2005. PMID: 16047352 Free article.
Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy.
Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, Fornage B, Singletary SE, Sahin A, Buzdar AU, Valero V. Hennessy BT, et al. Among authors: cristofanilli m. Cancer. 2006 Mar 1;106(5):1000-6. doi: 10.1002/cncr.21726. Cancer. 2006. PMID: 16444747 Free article. Clinical Trial.
A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach.
Cristofanilli M, Krishnamurthy S, Guerra L, Broglio K, Arun B, Booser DJ, Menander K, Van Wart Hood J, Valero V, Hortobagyi GN. Cristofanilli M, et al. Cancer. 2006 Sep 1;107(5):935-44. doi: 10.1002/cncr.22080. Cancer. 2006. PMID: 16874816 Free article. Clinical Trial.
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Liedtke C, et al. Among authors: cristofanilli m. J Clin Oncol. 2008 Mar 10;26(8):1275-81. doi: 10.1200/JCO.2007.14.4147. Epub 2008 Feb 4. J Clin Oncol. 2008. PMID: 18250347 Corrected and republished.
Prognostic significance of HER-2 status in women with inflammatory breast cancer.
Dawood S, Broglio K, Gong Y, Yang WT, Cristofanilli M, Kau SW, Meric-Bernstam F, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM; Inflammatory Breast Cancer Research Group. Dawood S, et al. Among authors: cristofanilli m. Cancer. 2008 May 1;112(9):1905-11. doi: 10.1002/cncr.23350. Cancer. 2008. PMID: 18300243 Free PMC article.
453 results